Results 61 to 70 of about 5,411 (177)

Removal of Toxic Metabolites—Chelation: Manganese Disorders

Journal of Inherited Metabolic Disease, Volume 48, Issue 6, November 2025.
ABSTRACT Manganese (Mn) overload is a characteristic of multiple disease entities, from acquired manganism upon environmental or occupational overexposure, to end‐stage liver disease and certain genetic disorders. The latter include hypermanganesaemia with dystonia 1 and 2 caused by pathogenic variants in the genes encoding the Mn transporters SLC30A10
Hendrik Vogt, George E. Kostakis, Rupert Purchase, John Spencer, Karin Tuschl   +4 more
wiley   +1 more source

Short‐term risks and benefits of hydroxyurea (hydroxycarbamide)‐induced transfusion independence in patients with beta‐thalassaemia syndromes

British Journal of Haematology, Volume 207, Issue 5, Page 2196-2199, November 2025.
Clinical outcomes of hydroxyurea (hydroxycarbamide)‐induced transfusion independence in patients with β‐thalassaemia syndromes.
B. R. Sevanthini, Santhosh Hegde, Tejashree Sridhar, Deepa Trivedi, Mohan Reddy, Vaibhav Shah, Vidhi Mayur Panchamia, T. Geetha, Dharmik Vora, H. Pushpa, Rajat Kumar Agarwal, Lawrence Faulkner   +11 more
wiley   +1 more source

The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR Β-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE

Mediterranean Journal of Hematology and Infectious Diseases, 2020
Background: The four most commonly used chelation regimens for β-thalassemia major patients in China are a combination therapy of deferoxamine and deferiprone (DFO+DFP), deferoxamine(DFO) monotherapy, deferiprone(DFP) monotherapy and deferasirox(DFX ...
Jialian Li
doaj   +1 more source

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction

Journal of Cardiovascular Magnetic Resonance, 2008
Background In thalassemia major (TM), severe cardiac siderosis can be treated by continuous parenteral deferoxamine, but poor compliance, complications and deaths occur.
Pibiri Martina, Agus Annalisa, Westwood Mark A, Smith Gillian C, Dessi Carlo, Galanello Renzo, Tanner Mark A, Nair Sunil V, Walker J Malcolm, Pennell Dudley J   +9 more
doaj   +1 more source

Challenges of Iron Chelation in Thalassemic Children

Thalassemia Reports
Thalassemia treatment still relies on supportive care, mainly including blood transfusion and iron chelation therapy. Iron chelation is considered the main factor responsible for the marked improvement in survival rates of thalassemic patients ...
Alkistis Adramerina, Marina Economou
doaj   +1 more source

Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.

PLoS ONE, 2016
UnlabelledAntiretrovirals suppress HIV-1 production yet spare the sites of HIV-1 production, the HIV-1 DNA-harboring cells that evade immune detection and enable viral resistance on-drug and viral rebound off-drug.
Deepti Saxena, Michael Spino, Fernando Tricta, John Connelly, Bernadette M Cracchiolo, Axel-Rainer Hanauske, Darlene D'Alliessi Gandolfi, Michael B Mathews, Jonathan Karn, Bart Holland, Myung Hee Park, Tsafi Pe'ery, Paul E Palumbo, Hartmut M Hanauske-Abel   +13 more
doaj   +1 more source

The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study

Journal of Cardiovascular Magnetic Resonance, 2009
Background Available iron chelation regimes in thalassaemia may achieve different changes in cardiac and hepatic iron as assessed by MR. The aim of this study was to assess the efficacy of four available iron chelator regimes in 232 thalassaemia major ...
Berdoussi Eleni, Zannikos Kirykos, Moraitis Panagiotis, Chouliaras Giorgos, Berdoukas Vasilios, Ladis Vassilios   +5 more
doaj   +1 more source

The Evaiuation of chalator therapy in reducing serum ferritin and improving Ejection fraction (EF%) in thalassemic patients

Iranian South Medical Journal, 2015
Background: Thalassemic syndroms are the most common genetic disease in the world that related to blood transfusion and iron overload in the body. Cardiac complications are the leading cause of death in patients with thalassemia.
Saeadh Firouzbakhtkh, Khadejeh Ghasemi, Nilofar Motamed, Mahmoodreza Sarrikhani   +3 more
doaj  

Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children

, 2021
Isita Tripathy, Amrita Panja, Tuphan Kanti Dolai, Asim Kumar Mallick   +3 more
openalex   +2 more sources

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes

Drug Design, Development and Therapy, 2016
Christina N Kontoghiorghe, George J Kontoghiorghes Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus Abstract: The prevalence rate of thalassemia, which is endemic in Southeast Asia, the Middle East, and
Kontoghiorghe CN, Kontoghiorghes GJ
doaj